Seko et al. conducted a retrospective study that compared treatment between SGLT2 inhibitors and DPP-4 inhibitors in T2DM patients with biopsy proven NAFLD. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.